Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines - 2Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike
- 3Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- 4Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- 5Rights group: At least 2,500 deaths during protest crackdown in Iran
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Vote In favor of Your #1 Electric Vehicles
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Fundamental Venture The board Apparatuses for Remote Groups
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Step by step instructions to Remain Spurred While Chasing after a Web-based Degree
- Dominating the Art of Composing: Creator Bits of knowledge
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
